

Multidrug therapy against leprosy

**Development and implementation
over the past 25 years**



**World Health Organization
Geneva
2004**

WHO Library Cataloguing-in-Publication Data

Multidrug therapy against leprosy : development and implementation over the past 25 years
/ [editor]: H. Sansarricq.

1.Leprosy - drug therapy 2.Leprostatic agents - therapeutic use 3.Drug therapy, Combination 4.Health plan implementation - trends 5.Program development 6.World Health Organization I.Sansarricq, Hubert.

ISBN 92 4 159176 5 (NLM classification: WC 335) WHO/CDS/CPE/CEE/2004.46

© World Health Organization 2004

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

Contents

| | |
|---|------------|
| Acknowledgements | v |
| Foreword <i>Carlos Morel</i> | vii |
| Introduction | 1 |
| The saga of dapsone <i>M.F. Lechat</i> | |
| Improved knowledge and new hopes <i>H. Sansarricq, S.R. Pattyn</i> | |
| The UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases <i>V. Pannikar</i> | |
| Chapter 1. Preparation of the Study Group on Chemotherapy of Leprosy | 19 |
| 1.1 Scientific factors (1972–1981) | 19 |
| <i>L. Levy</i> | |
| 1.2 Increasing role of voluntary organizations | 25 |
| The Japan Shipbuilding Industry Foundation and the Sasakawa Memorial Health Foundation <i>Y. Yuasa</i> | |
| The International Federation of Anti-Leprosy Associations <i>H. Sansarricq</i> | |
| Chapter 2. The Study Group | 31 |
| <i>H. Sansarricq</i> | |
| 2.1 The problem | 31 |
| Effective and practical MDT in sight? | |
| The anarchic use of rifampicin | |
| A strong demand for WHO recommendations | |
| The response from WHO | |
| 2.2 The meeting | 35 |
| Design of the meeting | |
| Progress in discussions | |
| The final report | |

| | |
|--|-----------|
| Chapter 3. Implementation of MDT | 45 |
| 3.1 Successive steps | 45 |
| <i>D. Daumerie</i> | |
| Main events, 1982 onwards | |
| 1982–1985: Introduction of MDT | |
| 1986–1990: Expansion of MDT into the “less difficult” areas | |
| 1991–2000: Elimination of leprosy as a public health problem | |
| 2000 onwards: the Final Push | |
| 3.2 Some important factors contributing to the implementation of WHO MDT | 58 |
| <i>M.F. Lechat</i> | |
| Wide acceptance of MDT | |
| Extremely low relapse rates after MDT treatment | |
| 3.3 Technical difficulties in the expansion of MDT | 64 |
| <i>S.K. Noordeen</i> | |
| Chapter 4. The role of countries | 69 |
| 4.1 Implementation of WHO MDT in Brazil | 69 |
| <i>A. Andrade</i> | |
| Serious reservations about the introduction of WHO MDT | |
| Treatment regimens tested | |
| Factors that convinced the experts to adopt the WHO MDT regimen | |
| Adjustment of the norms and guidelines of the leprosy control programme to implement WHO MDT | |
| Changes in the epidemiological situation, impact, side-effects, relapses, and cure | |
| The impact of MDT | |
| Lessons learned | |
| 4.2 Implementation of MDT in Burkina Faso | 82 |
| <i>A. Tiendrebeogo, L. Some</i> | |
| Introduction of MDT: 1981–1988 | |
| Extension of MDT coverage: 1989–1993 | |
| Leprosy elimination: 1994–2000 | |
| 4.3 Implementation of WHO MDT in India 1982–2001 | 92 |
| <i>C.K. Rao</i> | |
| Progress | |
| Developments | |
| Conclusion | |

| | | |
|-------------------|--|------------|
| 4.4 | Implementation of WHO MDT in Myanmar | 106 |
| | <i>Kyaw Lwin, Tin Myint, Mg Mg Gyi, Mya Thein, Tin Shwe, Kyaw Nyunt Sein</i> | |
| | History of leprosy | |
| | Leprosy control in Myanmar | |
| | Situation during the early 1980s | |
| | Challenges faced | |
| | Finding alternative regimens (1981–1986) | |
| | Introduction of WHO MDT, 1988 | |
| | Expansion of MDT coverage, 1995–1996 | |
| | Achievements due to integrated MDT services | |
| | Conclusion | |
| 4.5 | Implementation of WHO MDT in the Philippines, 1981–2000 | 117 |
| | <i>S.S. Griño</i> | |
| | The pilot study | |
| | National leprosy control programme | |
| | Strengths – factors that contributed to success | |
| | Conclusion | |
| Chapter 5. | The role of international agencies and nongovernmental organizations | 127 |
| 5.1 | The Nippon Foundation (formerly Japan Shipbuilding Industry Foundation) and the Sasakawa Memorial Health Foundation | 127 |
| | <i>Y. Yuasa</i> | |
| 5.2 | The International Federation of Anti-Leprosy Associations | 129 |
| | <i>H. Sansarricq</i> | |
| | 1981–1990: continuing good ILEP/WHO cooperation, with a few clouds | |
| | 1991–2000: growing difficulties in ILEP/WHO cooperation | |
| 5.3 | Novartis | 135 |
| | <i>S.J. Yawalkar, P. Grewal</i> | |
| | Drug development | |
| | Contribution to implementation of WHO MDT | |
| Chapter 6. | The role of WHO including TDR | 143 |
| 6.1 | The WHO Leprosy unit | 143 |
| | Overview | |
| | <i>S.K. Noordeen</i> | |
| | Detailed account | |
| | <i>H. Sansarricq</i> | |

| | | |
|-------------------|---|------------|
| 6.2 | THELEP | 160 |
| | <i>L. Levy</i> | |
| | Surveys of dapsone resistance | |
| | Information regarding antileprosy drugs | |
| | Participation in the 1981 Study Group and in subsequent technical meetings related to chemotherapy of leprosy | |
| 6.3 | Evolution in WHO, including TDR/THELEP, from 1991 to 2000 | 165 |
| | Intensive elimination strategy | |
| | <i>S.K. Noordeen</i> | |
| | Changes in research focus | |
| | <i>L. Levy</i> | |
| Chapter 7. | Lessons to be learned | 171 |
| | <i>H. Sansarricq</i> | |
| 7.1 | MDT development | 171 |
| | Overview | |
| | MDT drugs | |
| | THELEP | |
| | Moving closer to the Study Group regimens | |
| | Conclusion | |
| 7.2 | 1982–1990: the first years of MDT implementation | 173 |
| | MDT coverage | |
| | Technical aspects | |
| | The reasons for success | |
| | Conclusion | |
| 7.3 | 1991–2000: elimination strategy..... | 175 |
| | Resolution WHA44.9 and plan for elimination of leprosy as a public health problem | |
| | Implementation of the elimination strategy | |
| 7.4 | 2000 onwards: the final push | 178 |
| 7.5 | Current concerns | 178 |

Acknowledgements

The Editor wishes to thank the persons listed below for their special written contributions and for providing background data.

Dr H. Sansarricq, Editor

Contributors

Dr V.L. Gomes de Andrade (Brazil); Mrs S.S. Griño (Philippines); Drs Kyaw Lwin, Tin Myint, Mg Mg Gyi, Mya Thein, Tin Shwe, Kyaw Nyunt Sein (Myanmar); Professor M.F. Lechat (Belgium); Dr L. Levy (Israel); Dr S.K. Noordeen (India); Dr S.R. Pattyn (Belgium); Dr C.K. Rao (India); Dr L. Some and Dr A. Tiendrebeogo (Burkina Faso); Professor S.J. Yawalkar and Mrs P. Grewal (Switzerland); Dr Y. Yuasa (Japan).

WHO Secretariat

Dr D. Daumerie; Dr V. Pannikar.

* * * * *

The Leprosy Programme would like to pay special tribute to Dr Hubert Sansarricq. Using his broad knowledge of the Programme's work, he participated extensively in the preparation of the report, generously dedicating much of his time to this substantial undertaking.

Special thanks are also addressed to our English Editor, Mrs Sarah Balance.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30094

